DO & CO Crecimiento futuro
Future controles de criterios 4/6
Se prevé un crecimiento anual de los beneficios y los ingresos de DO & CO de 18.4% y 6.8% por año respectivamente. Se prevé que el BPA crezca en un 17.4% al año. Se espera que la rentabilidad financiera sea de 23.9% en 3 años.
Información clave
18.4%
Tasa de crecimiento de los beneficios
17.4%
Tasa de crecimiento del BPA
Crecimiento de los beneficios de Commercial Services | 16.5% |
Tasa de crecimiento de los ingresos | 6.8% |
Rentabilidad financiera futura | 23.9% |
Cobertura de analistas | Low |
Última actualización | 18 Nov 2024 |
Actualizaciones recientes sobre el crecimiento futuro
Recent updates
Does DO & CO (VIE:DOC) Deserve A Spot On Your Watchlist?
Nov 13We Think DO & CO (VIE:DOC) Might Have The DNA Of A Multi-Bagger
Oct 24Is DO & CO Aktiengesellschaft (VIE:DOC) Potentially Undervalued?
Aug 28DO & CO Aktiengesellschaft's (VIE:DOC) Price In Tune With Earnings
Aug 04Earnings Update: DO & CO Aktiengesellschaft (VIE:DOC) Just Reported Its Annual Results And Analysts Are Updating Their Forecasts
Jun 30DO & CO (VIE:DOC) Could Easily Take On More Debt
Jun 28DO & CO (VIE:DOC) Shareholders Will Want The ROCE Trajectory To Continue
May 30At €149, Is DO & CO Aktiengesellschaft (VIE:DOC) Worth Looking At Closely?
May 13DO & CO (VIE:DOC) Could Easily Take On More Debt
Mar 07We Think DO & CO's (VIE:DOC) Robust Earnings Are Conservative
Feb 22Shareholders Should Be Pleased With DO & CO Aktiengesellschaft's (VIE:DOC) Price
Feb 05At €133, Is It Time To Put DO & CO Aktiengesellschaft (VIE:DOC) On Your Watch List?
Dec 26Is There An Opportunity With DO & CO Aktiengesellschaft's (VIE:DOC) 48% Undervaluation?
Nov 17The Returns At DO & CO (VIE:DOC) Aren't Growing
Oct 13DO & CO (VIE:DOC) Has A Pretty Healthy Balance Sheet
Sep 19At €119, Is It Time To Put DO & CO Aktiengesellschaft (VIE:DOC) On Your Watch List?
Jul 27Returns On Capital At DO & CO (VIE:DOC) Have Stalled
Jun 30Is DO & CO Aktiengesellschaft (VIE:DOC) Trading At A 42% Discount?
Jun 17Is It Time To Consider Buying DO & CO Aktiengesellschaft (VIE:DOC)?
Apr 03An Intrinsic Calculation For DO & CO Aktiengesellschaft (VIE:DOC) Suggests It's 38% Undervalued
Mar 16DO & CO's (VIE:DOC) Returns On Capital Not Reflecting Well On The Business
Oct 18DO & CO (VIE:DOC) Has A Pretty Healthy Balance Sheet
Sep 24Is There Now An Opportunity In DO & CO Aktiengesellschaft (VIE:DOC)?
Aug 25Does DO & CO (VIE:DOC) Have A Healthy Balance Sheet?
May 11Returns On Capital At DO & CO (VIE:DOC) Paint A Concerning Picture
Mar 26DO & CO (VIE:DOC) Has A Pretty Healthy Balance Sheet
Feb 09Why DO & CO's (VIE:DOC) Earnings Are Better Than They Seem
Nov 25Capital Allocation Trends At DO & CO (VIE:DOC) Aren't Ideal
Nov 09Does DO & CO (VIE:DOC) Have A Healthy Balance Sheet?
Jul 18An Intrinsic Calculation For DO & CO Aktiengesellschaft (VIE:DOC) Suggests It's 38% Undervalued
Apr 03What Kind Of Shareholders Own DO & CO Aktiengesellschaft (VIE:DOC)?
Feb 27Revenue Downgrade: Here's What Analysts Forecast For DO & CO Aktiengesellschaft (VIE:DOC)
Jan 21DO & CO's(VIE:DOC) Share Price Is Down 32% Over The Past Five Years.
Jan 17Is DO & CO (VIE:DOC) Using Debt In A Risky Way?
Dec 21Are Investors Undervaluing DO & CO Aktiengesellschaft (VIE:DOC) By 40%?
Nov 25Previsiones de crecimiento de beneficios e ingresos
Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
---|---|---|---|---|---|
3/31/2027 | 2,432 | 127 | 154 | 209 | 4 |
3/31/2026 | 2,267 | 112 | 133 | 194 | 5 |
3/31/2025 | 2,148 | 92 | 102 | 171 | 2 |
6/30/2024 | 1,970 | 69 | 85 | 171 | N/A |
3/31/2024 | 1,819 | 66 | 103 | 180 | N/A |
12/31/2023 | 1,739 | 61 | 140 | 213 | N/A |
9/30/2023 | 1,632 | 55 | 120 | 176 | N/A |
6/30/2023 | 1,532 | 46 | 91 | 133 | N/A |
3/31/2023 | 1,419 | 34 | 77 | 114 | N/A |
12/31/2022 | 1,249 | 22 | 41 | 69 | N/A |
9/30/2022 | 1,086 | 17 | 43 | 66 | N/A |
6/30/2022 | 891 | 12 | 39 | 61 | N/A |
3/31/2022 | 705 | 11 | 50 | 67 | N/A |
12/31/2021 | 559 | 12 | 52 | 71 | N/A |
9/30/2021 | 428 | 7 | 27 | 48 | N/A |
6/30/2021 | 324 | -14 | 25 | 52 | N/A |
3/31/2021 | 253 | -38 | -9 | 27 | N/A |
12/31/2020 | 365 | -82 | -34 | 28 | N/A |
9/30/2020 | 539 | -77 | -21 | 68 | N/A |
6/30/2020 | 720 | -53 | -21 | 76 | N/A |
3/31/2020 | 935 | -25 | 7 | 103 | N/A |
12/31/2019 | 956 | 26 | 43 | 114 | N/A |
9/30/2019 | 922 | 25 | 20 | 73 | N/A |
6/30/2019 | 881 | 27 | 18 | 64 | N/A |
3/31/2019 | 848 | 26 | 13 | 55 | N/A |
12/31/2018 | 841 | 27 | -10 | 33 | N/A |
9/30/2018 | 845 | 28 | -7 | 46 | N/A |
6/30/2018 | 856 | 25 | -36 | 30 | N/A |
3/31/2018 | 861 | 24 | N/A | 42 | N/A |
12/31/2017 | 848 | 19 | N/A | 60 | N/A |
9/30/2017 | 860 | 18 | N/A | 46 | N/A |
6/30/2017 | 879 | 19 | N/A | 37 | N/A |
3/31/2017 | 913 | 21 | N/A | 56 | N/A |
12/31/2016 | 943 | 25 | N/A | 46 | N/A |
9/30/2016 | 946 | 24 | N/A | 79 | N/A |
6/30/2016 | 942 | 28 | N/A | 107 | N/A |
3/31/2016 | 916 | 28 | N/A | 92 | N/A |
12/31/2015 | 912 | 30 | N/A | 84 | N/A |
9/30/2015 | 879 | 29 | N/A | 66 | N/A |
6/30/2015 | 839 | 33 | N/A | 67 | N/A |
3/31/2015 | 799 | 35 | N/A | 66 | N/A |
12/31/2014 | 751 | 35 | N/A | 58 | N/A |
9/30/2014 | 701 | 37 | N/A | 70 | N/A |
6/30/2014 | 664 | 30 | N/A | 42 | N/A |
3/31/2014 | 636 | 26 | N/A | 41 | N/A |
12/31/2013 | 617 | 24 | N/A | 33 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (18.4% al año) de DOC es superior a la tasa de ahorro (1.4%).
Beneficios vs. Mercado: Se prevé que los beneficios (18.4% al año) de DOC crezcan más rápidamente que el mercado Austrian (8.8% al año).
Beneficios de alto crecimiento: Se prevé que los beneficios de DOC crezcan, pero no significativamente.
Ingresos vs. Mercado: Se prevé que los ingresos (6.8% al año) de DOC crezcan más rápidamente que los del mercado Austrian (0.8% al año).
Ingresos de alto crecimiento: Se prevé que los ingresos 6.8% al año) de DOC crezcan más despacio que 20% al año.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Se prevé que la rentabilidad financiera de DOC sea alta dentro de 3 años (23.9%)